港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

九源基因

8.030

-0.210-2.55%

成交量：3.66万

成交额：29.79万

市值：19.43亿

市盈率：11.83

高：8.380

开：8.380

低：8.030

收：8.240

52周最高：16.290

52周最低：5.330

股本：2.42亿

香港流通股本：1.06亿

量比：2.19

换手率：0.03%

股息：0.06

股息率：0.79%

每股收益(LYR):0.679

净资产收益率：9.48%

总资产收益率：4.45%

市净率：1.07

市盈率(LYR):11.83

市销率: 1.31

数据加载中...

总览公司新闻资讯公告

九源基因（02566）公布1月股份变动月报，合计回购约77.44万股H股

九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可

九源基因Jy47注射液临床试验申请获国家药监局批准

九源基因(02566.HK)公众持股量约为22.22%

九源基因(02566)公告：公众持股量降至22.22% 正研究恢复至25%最低比例

九源基因（02566）2月回购3,108,000股H股，注册股本维持245,398,800股

九源基因(02566)股价下跌5.333%，现价港币$8.52

阿斯达克财经

国产减重药迎突破！九源基因司美格鲁肽申报上市瞄准百亿美元赛道

大湾区经济网

九源基因(02566)：吉可亲®上市申请获国家药品监督管理局受理

九源基因(02566)股价下跌6.466%，现价港币$8.68

阿斯达克财经

九源基因2026年关注点：司美格鲁肽专利到期与新品临床试验

九源基因盘中异动股价大涨8.49%

九源基因(02566)股价下跌5.01%，现价港币$9.1

阿斯达克财经

九源基因(02566)2月12日耗资约25.53万港元回购2.6万股

九源基因(02566)2月11日斥资8.51万港元回购8600股

杭州九源基因生物医药(02566)回购8,600股H股，占已发行股本约0.00817%

杭州九源基因(02566)回购约28.52万股H股，总额约287万港元

九源基因(02566)2月9日斥资60.59万港元回购6.08万股

杭州九源基因（02566）回购6.08万股股份，总额约60.59万港元

助血糖控制及体重管理九源基因(02566.HK)JY54注射液临床试验申请获受理

阿斯达克财经

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02566/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02566","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":8.03,"timestamp":1773984780776,"preClose":8.24,"halted":0,"volume":36600,"delay":0,"changeRate":-0.025485436893203987,"floatShares":106000000,"shares":242000000,"eps":0.678655,"marketStatus":"交易中","change":-0.21,"latestTime":"03-20 13:48:34","open":8.38,"high":8.38,"low":8.03,"amount":297888,"amplitude":0.042476,"askPrice":8.08,"askSize":200,"bidPrice":8.03,"bidSize":1800,"shortable":0,"etf":0,"ttmEps":0.559,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773994200000},"marketStatusCode":2,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":8.24,"dividendRate":0.007854,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":2.192683,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","floatShares":106000000,"roa":"4.45%","roe":"9.48%","lyrEps":0.678655,"volumeRatio":2.192683,"shares":242000000,"dividePrice":0.063586,"high":8.38,"amplitude":0.042476,"preClose":8.24,"low":8.03,"week52Low":5.33,"pbRate":"1.07","psRate":"1.31","week52High":16.29,"institutionHeld":0,"latestPrice":8.03,"committee":0.8,"eps":0.678655,"divideRate":0.007919,"volume":36600,"delay":0,"ttmEps":0.559,"open":8.38,"prevYearClose":7.56,"prevWeekClose":7.83,"prevMonthClose":9,"prevQuarterClose":7.56,"fiveDayClose":7.83,"twentyDayClose":9.19,"sixtyDayClose":7.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02566\",params:#limit:5,,,undefined,":[{"date":"2025-08-18","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-06-13","symbol":"02566","amount":0.056,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-16","defaultRemindTime":1749778200000,"name":"九源基因","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-06-16","currency":"CNY","dateTimestamp":1749744000000,"payDate":"2025-07-30"},{"date":"2025-03-26","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"","dateTimestamp":1742918400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02566\",market:\"HK\",,,undefined,":[{"executeDate":"2025-06-13","recordDate":"2025-06-16","paymentDate":"2025-07-30","value":0.056,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02566\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02566\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02566","date":"2026-03-19","current":14.543828,"percent":0.555205,"low":9.307514,"twenty":11.02367,"median":13.982914,"eighty":17.266358,"high":28.852596,"avg":14.795306,"sd":4.224032,"marketCap":1990095136},"quantilePoints":[{"date":"2024-12-06","current":14.097915,"twenty":14.208262,"median":14.275695,"eighty":14.595644,"marketCap":1946012484},{"date":"2024-12-13","current":13.217326,"twenty":13.348436,"median":13.95821,"eighty":14.334483,"marketCap":1820859096},{"date":"2024-12-20","current":12.20261,"twenty":12.40882,"median":13.381214,"eighty":14.243818,"marketCap":1673619816},{"date":"2024-12-27","current":12.158366,"twenty":12.254449,"median":13.1954,"eighty":14.180675,"marketCap":1666257852},{"date":"2025-01-03","current":11.126814,"twenty":12.0799,"median":12.46117,"eighty":14.042033,"marketCap":1526380536},{"date":"2025-01-10","current":9.714633,"twenty":11.141125,"median":12.29741,"eighty":13.763077,"marketCap":1327607508},{"date":"2025-01-17","current":9.904165,"twenty":10.518129,"median":12.180488,"eighty":13.509332,"marketCap":1354601376},{"date":"2025-01-24","current":10.07429,"twenty":9.9409,"median":12.04207,"eighty":13.348436,"marketCap":1386503220},{"date":"2025-01-28","current":10.358786,"twenty":9.995541,"median":11.819979,"eighty":13.282881,"marketCap":1433128992},{"date":"2025-02-07","current":11.238302,"twenty":10.0243,"median":11.162591,"eighty":13.191014,"marketCap":1546012440},{"date":"2025-02-14","current":11.154484,"twenty":10.062805,"median":11.126814,"eighty":12.776093,"marketCap":1533742500},{"date":"2025-02-21","current":12.73316,"twenty":10.073062,"median":11.193598,"eighty":12.735779,"marketCap":1757055408},{"date":"2025-02-28","current":11.508443,"twenty":10.189099,"median":11.508443,"eighty":12.653552,"marketCap":1582822260},{"date":"2025-03-07","current":12.084413,"twenty":10.276651,"median":11.554796,"eighty":12.584056,"marketCap":1668711840},{"date":"2025-03-14","current":12.91496,"twenty":10.28916,"median":11.611229,"eighty":12.584056,"marketCap":1784049276},{"date":"2025-03-21","current":12.244709,"twenty":10.311241,"median":11.810026,"eighty":12.735779,"marketCap":1690797732},{"date":"2025-03-28","current":11.696332,"twenty":10.344738,"median":11.831112,"eighty":12.72799,"marketCap":1734969516},{"date":"2025-04-03","current":10.807781,"twenty":10.395616,"median":11.800074,"eighty":12.674918,"marketCap":1600000176},{"date":"2025-04-11","current":9.828764,"twenty":10.27298,"median":11.65378,"eighty":12.589531,"marketCap":1445398932},{"date":"2025-04-17","current":9.988361,"twenty":10.075173,"median":11.569961,"eighty":12.56072,"marketCap":1472392800},{"date":"2025-04-25","current":10.079541,"twenty":10.050182,"median":11.463659,"eighty":12.511173,"marketCap":1487116728},{"date":"2025-05-02","current":10.290636,"twenty":10.067013,"median":11.287756,"eighty":12.494061,"marketCap":1467484824},{"date":"2025-05-09","current":10.406872,"twenty":10.062805,"median":11.203375,"eighty":12.472285,"marketCap":1494478692},{"date":"2025-05-16","current":10.339488,"twenty":10.073062,"median":11.154484,"eighty":12.457737,"marketCap":1496932680},{"date":"2025-05-23","current":10.443848,"twenty":10.076938,"median":11.100884,"eighty":12.429027,"marketCap":1516564584},{"date":"2025-05-30","current":10.499086,"twenty":10.079206,"median":11.063697,"eighty":12.408842,"marketCap":1531288512},{"date":"2025-06-06","current":10.405237,"twenty":10.102813,"median":10.92653,"eighty":12.402573,"marketCap":1521472560},{"date":"2025-06-13","current":16.776007,"twenty":10.127345,"median":11.063697,"eighty":12.429027,"marketCap":2453988000},{"date":"2025-06-20","current":13.783342,"twenty":10.148232,"median":11.100884,"eighty":12.535947,"marketCap":2012270160},{"date":"2025-06-27","current":13.241991,"twenty":10.175286,"median":11.154484,"eighty":12.72799,"marketCap":1938650520},{"date":"2025-07-04","current":14.247042,"twenty":10.191457,"median":11.198369,"eighty":12.80722,"marketCap":2085889800},{"date":"2025-07-11","current":16.12378,"twenty":10.199228,"median":11.287756,"eighty":13.164345,"marketCap":2358282468},{"date":"2025-07-18","current":16.959198,"twenty":10.204599,"median":11.508443,"eighty":13.325525,"marketCap":2478527880},{"date":"2025-07-25","current":16.429296,"twenty":10.22327,"median":11.606189,"eighty":13.872228,"marketCap":2409816216},{"date":"2025-08-01","current":16.329429,"twenty":10.25109,"median":11.703755,"eighty":14.068336,"marketCap":2380368360},{"date":"2025-08-08","current":17.296232,"twenty":10.27298,"median":11.825546,"eighty":14.242565,"marketCap":2527607640},{"date":"2025-08-15","current":25.546022,"twenty":10.28665,"median":12.04207,"eighty":14.454008,"marketCap":3727607772},{"date":"2025-08-22","current":27.152477,"twenty":10.291424,"median":12.068084,"eighty":15.48419,"marketCap":3646626168},{"date":"2025-08-29","current":24.186548,"twenty":10.297713,"median":12.158366,"eighty":16.326447,"marketCap":3263804040},{"date":"2025-09-05","current":26.17651,"twenty":10.31224,"median":12.214209,"eighty":16.547432,"marketCap":3528834744},{"date":"2025-09-12","current":23.22216,"twenty":10.322989,"median":12.270192,"eighty":16.690567,"marketCap":3136196664},{"date":"2025-09-19","current":21.82033,"twenty":10.32445,"median":12.326094,"eighty":16.958366,"marketCap":2944785600},{"date":"2025-09-26","current":20.564467,"twenty":10.331172,"median":12.407292,"eighty":17.223519,"marketCap":2768098464},{"date":"2025-10-03","current":22.006879,"twenty":10.341379,"median":12.455816,"eighty":17.606421,"marketCap":2969325480},{"date":"2025-10-10","current":19.015463,"twenty":10.348945,"median":12.489783,"eighty":18.310381,"marketCap":2561963472},{"date":"2025-10-17","current":16.970486,"twenty":10.358786,"median":12.586793,"eighty":18.134776,"marketCap":2284662828},{"date":"2025-10-24","current":16.253675,"twenty":10.405237,"median":12.724544,"eighty":17.900127,"marketCap":2188957296},{"date":"2025-10-31","current":15.392522,"twenty":10.406545,"median":12.739707,"eighty":17.871014,"marketCap":2076073848},{"date":"2025-11-07","current":13.654382,"twenty":10.406872,"median":12.862233,"eighty":17.830642,"marketCap":1840491000},{"date":"2025-11-14","current":13.652109,"twenty":10.414705,"median":13.150654,"eighty":17.669327,"marketCap":1845398976},{"date":"2025-11-21","current":13.022772,"twenty":10.429703,"median":12.977364,"eighty":17.532486,"marketCap":1759509396},{"date":"2025-11-28","current":14.151953,"twenty":10.441671,"median":13.150654,"eighty":17.476552,"marketCap":1919018616},{"date":"2025-12-05","current":15.0671,"twenty":10.446315,"median":13.212896,"eighty":17.360095,"marketCap":2046625992},{"date":"2025-12-12","current":15.021249,"twenty":10.450076,"median":13.373682,"eighty":17.303573,"marketCap":2044172004},{"date":"2025-12-19","current":13.906512,"twenty":10.4562,"median":13.596735,"eighty":17.18567,"marketCap":1896932724},{"date":"2025-12-24","current":13.468772,"twenty":10.460694,"median":13.541362,"eighty":17.140598,"marketCap":1842944988},{"date":"2026-01-02","current":13.594612,"twenty":10.472165,"median":13.526709,"eighty":17.103787,"marketCap":1867484868},{"date":"2026-01-09","current":14.184539,"twenty":10.508332,"median":13.623361,"eighty":17.043007,"marketCap":1953374448},{"date":"2026-01-16","current":15.82386,"twenty":10.552044,"median":13.654647,"eighty":16.970089,"marketCap":2186209278},{"date":"2026-01-23","current":17.221546,"twenty":10.59039,"median":13.760784,"eighty":17.043007,"marketCap":2377029620},{"date":"2026-01-30","current":18.645413,"twenty":10.66635,"median":13.818506,"eighty":17.208843,"marketCap":2585326030},{"date":"2026-02-06","current":17.570145,"twenty":10.791312,"median":13.890789,"eighty":17.500019,"marketCap":2442411318},{"date":"2026-02-13","current":16.566637,"twenty":10.808038,"median":13.930604,"eighty":17.447639,"marketCap":2316142276},{"date":"2026-02-20","current":15.898541,"twenty":10.808553,"median":13.936612,"eighty":17.405456,"marketCap":2219535716},{"date":"2026-02-27","current":15.400942,"twenty":10.876548,"median":13.991046,"eighty":17.345071,"marketCap":2173647600},{"date":"2026-03-06","current":14.146009,"twenty":10.927529,"median":14.014987,"eighty":17.323365,"marketCap":1980434480},{"date":"2026-03-13","current":13.445786,"twenty":10.970802,"median":13.989227,"eighty":17.304533,"marketCap":1891073412},{"date":"2026-03-19","current":14.203626,"twenty":11.02367,"median":13.982914,"eighty":17.266358,"marketCap":1990095136}],"updateTime":1773977326648},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02566\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1125248160","title":"九源基因（02566）公布1月股份变动月报，合计回购约77.44万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125248160","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125248160?lang=zh_cn&edition=fundamental","pubTime":"2026-03-18 18:21","pubTimestamp":1773829312,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年3月18日披露2026年1月股份变动月报表，报告期为2026年1月。截至本月末，公司注册股本人民币245,398,800元，其中包括三类股份：H股、内资股及非上市外资股。H股方面，月初已发行流通股份数量为109,096,785股，当月合计回购774,400股，并将其持作库存股份，导致H股流通股份减少至108,322,385股，库存股份则增至774,400股。内资股和非上市外资股数量分别维持在105,302,015股及31,000,000股，报告期内无变动。截至1月末，公司股本总数保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2620430440","title":"九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2620430440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620430440?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 17:21","pubTimestamp":1773739274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1110359935","title":"九源基因Jy47注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1110359935","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110359935?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 17:20","pubTimestamp":1773739217,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其Jy47注射液的临床试验申请已获得国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2617854431","title":"九源基因(02566.HK)公众持股量约为22.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617854431","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617854431?lang=zh_cn&edition=fundamental","pubTime":"2026-03-05 20:07","pubTimestamp":1772712421,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨九源基因(02566.HK)公告，于本公告日期，公司的公众持股量约为22.22%，已低于上市规则第19A.28B条所规定公众股东持有公司已发行股份总数的25.0%(\"最低规定百分比\")。\r\n\r\n　　公司公众持股量的不足，乃由于近期根据公司股东于2025年6月11日举行的股东周年大会上授予董事会的购回授权，回购公司H股所致，使得其中一名公众股东转变成为上市规则所定义的主要股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1152661765","title":"九源基因(02566)公告：公众持股量降至22.22% 正研究恢复至25%最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1152661765","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152661765?lang=zh_cn&edition=fundamental","pubTime":"2026-03-05 19:51","pubTimestamp":1772711502,"startTime":"0","endTime":"0","summary":"九源基因于2026年3月5日发布公告，指出上市公司公众持股量约为22.22%，低于香港联合交易所有限公司证券上市规则所要求的最低25%规定。据悉，主要原因在于根据2025年6月11日股东周年大会上授予董事会的购回授权回购H股后，一名原本属于公众持股范围的股东转变为上市规则定义的主要股东，导致公众持股量减少。公司预计自公告日期起六个月内恢复公众持股量，但仍需董事会和监管机构批准，并视乎市场情况而定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"1144352339","title":"九源基因（02566）2月回购3,108,000股H股，注册股本维持245,398,800股","url":"https://stock-news.laohu8.com/highlight/detail?id=1144352339","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144352339?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 17:41","pubTimestamp":1772617313,"startTime":"0","endTime":"0","summary":"九源基因于2026年3月4日披露了截至2026年2月28日的股份变动月报表。公告显示，公司本月注册股本保持人民币245,398,800元不变，未有新增发行或注销事项。本月内，公司H股总数维持109,096,785股，其中流通中的已发行股份由上月底的108,322,385股减少至105,214,385股，变化主要因回购3,108,000股H股所致。这些回购股份尚未注销，暂以库存股份形式持有，数量由774,400股增至3,882,400股。内资股与非上市外资股方面，数量分别保持105,302,015股与31,000,000股，均无变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2616389893","title":"九源基因(02566)股价下跌5.333%，现价港币$8.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389893","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616389893?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 15:45","pubTimestamp":1772437500,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在下午03:45比前收市价下跌5.333%，现股价为港币$8.52。至目前为止，今日最高价为$9.0，而最低价为$8.52。总成交量为11.24万股，总成交金额为港币$98.15万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603028423/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603028423/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614029090","title":"国产减重药迎突破！九源基因司美格鲁肽申报上市 瞄准百亿美元赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029090","media":"大湾区经济网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614029090?lang=zh_cn&edition=fundamental","pubTime":"2026-02-26 10:12","pubTimestamp":1772071957,"startTime":"0","endTime":"0","summary":"在国内司美格鲁肽减重适应症领域，公司属于少数已完成上市申报并进入审评阶段的企业之一。相关产品如顺利获批，有望成为国内首个以生物法实现产业化的司美格鲁肽减重药物。公开数据显示，司美格鲁肽减重产品在中国市场实现快速增长，2025年诺和诺德司美格鲁肽减重版注射液中国区销售额为1.21亿美元，同比激增314%，市场对高品质减重药物的需求日益迫切。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614608029","title":"九源基因(02566)：吉可亲®上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608029","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614608029?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 21:44","pubTimestamp":1772027076,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，集团开发的吉可亲的上市申请已获中国国家药监局受理。吉可亲于2024年1月获得国家药品监督管理局签发的药物临床试验批准通知书，并于2024年12月完成Ⅲ期临床研究全部受试者入组，目前已完成试验，上市申请相关申报资料已递交国家药品审评中心进行审评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因(02566)：吉可亲®上市申请获国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2613697761","title":"九源基因(02566)股价下跌6.466%，现价港币$8.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2613697761","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613697761?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 13:30","pubTimestamp":1771911000,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在下午01:30比前收市价下跌6.466%，现股价为港币$8.68。至目前为止，今日最高价为$9.2，而最低价为$8.68。总成交量为1.52万股，总成交金额为港币$13.738万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602245606/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602245606/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2613733439","title":"九源基因2026年关注点：司美格鲁肽专利到期与新品临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733439","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733439?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 17:43","pubTimestamp":1771839834,"startTime":"0","endTime":"0","summary":"来源：经济观察网经济观察网 根据公开信息，九源基因在2026年有以下值得关注的事件：行业政策与环境司美格鲁肽专利到期及市场竞争变化：司美格鲁肽核心专利将于2026年3月后到期，预计国产司美格鲁肽将进入市场竞争加剧的阶段，九源基因是申报该产品的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2613207749","title":"九源基因盘中异动 股价大涨8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613207749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613207749?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 09:31","pubTimestamp":1771810290,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘09时31分，九源基因股票出现波动，股价急速上涨8.49%。截至发稿，该股报9.970港元/股，成交量1.1万股，换手率0.01%，振幅0.00%。九源基因股票所在的药品行业中，整体涨幅为0.27%。其相关个股中，九源基因、德琪医药-B、长风药业涨幅较大，振幅较大的相关个股有康龙化成、康哲药业、中国同辐，振幅分别为3.48%、2.38%、2.34%。九源基因公司简介：杭州九源基因工程有限公司是一家主要从事基因药物研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2612255839","title":"九源基因(02566)股价下跌5.01%，现价港币$9.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2612255839","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612255839?lang=zh_cn&edition=fundamental","pubTime":"2026-02-20 11:21","pubTimestamp":1771557660,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在上午11:21比前收市价下跌5.01%，现股价为港币$9.1。至目前为止，今日最高价为$9.58，而最低价为$9.1。总成交量为2.72万股，总成交金额为港币$25.379万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602203754/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602203754/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610794209","title":"九源基因(02566)2月12日耗资约25.53万港元回购2.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794209","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794209?lang=zh_cn&edition=fundamental","pubTime":"2026-02-12 19:03","pubTimestamp":1770894192,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)公布，2026年2月12日耗资约25.53万港元回购2.6万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610936857","title":"九源基因(02566)2月11日斥资8.51万港元回购8600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936857?lang=zh_cn&edition=fundamental","pubTime":"2026-02-11 18:54","pubTimestamp":1770807244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，该公司于2026年2月11日斥资8.51万港元回购8600股股份，每股回购价格为9.89-9.9港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1114194197","title":"杭州九源基因生物医药(02566)回购8,600股H股，占已发行股本约0.00817%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114194197","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114194197?lang=zh_cn&edition=fundamental","pubTime":"2026-02-11 18:45","pubTimestamp":1770806730,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年2月11日发布翌日披露报表，公告公司于当日回购8,600股H股，约占公司回购前已发行股份总数的0.00817%。本次回购价格介乎每股9.89港元至9.90港元，总金额约85,107.9994港元。公司亦披露，剩余回购授权基于2025年6月11日通过的议案，授权总数为10,909,678股，此前已回购3,856,400股。公司在公告中确认，此次回购遵守香港联交所证券上市规则及相关法律规定，相关董事会授权亦已获得正式批准。公告由联席公司秘书黄秀签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"1103066878","title":"杭州九源基因(02566)回购约28.52万股H股，总额约287万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103066878","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103066878?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 19:01","pubTimestamp":1770721311,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司(02566)于2026年2月10日发布翌日披露报表，披露当日回购285,200股H股，占回购前公司已发行股份（不包括库藏股）的约0.27024%。\n本次回购于香港联交所进行，价格区间介于每股9.83港元至10.30港元之间，合计支付约2,870,506.048港元。根据2025年6月11日获通过的购回授权，公司剩余可回购股份数为10,909,678股。回购完成后，公司已发行股份总数维持在109,096,785股，其中流通股为105,248,985股，库藏股为3,847,800股。\n公司确认已严格遵守相关上市规则及法律规定。公告由联席公司秘书黄秀签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610756637","title":"九源基因(02566)2月9日斥资60.59万港元回购6.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610756637","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610756637?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 20:13","pubTimestamp":1770639185,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，于2026年2月9日，该公司斥资60.59万港元回购6.08万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"1194403275","title":"杭州九源基因（02566）回购6.08万股股份，总额约60.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194403275","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194403275?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 19:51","pubTimestamp":1770637908,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年2月9日公布翌日披露报表，披露当日回购60,800股H股股份，约占回购前已发行股本的0.05758%。本次回购每股价格在每股港币9.81元至10元区间，总额约港币60.59万元。据公告显示，本次回购基于2025年6月11日通过的回购授权进行，公司目前可回购股份总数为10,909,678股，截至公告日已回购3,562,600股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。公告由联席公司秘书黄秀签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610633921","title":"助血糖控制及体重管理  九源基因(02566.HK)JY54注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633921","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610633921?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 17:04","pubTimestamp":1770627840,"startTime":"0","endTime":"0","summary":"九源基因宣布，公司自主开发的化学1类创新药“JY54注射液”新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。公司计划开展“JY54注射液”用于肥胖或超重人群体重管理的Ⅰ期临床研究，该研究旨在评价“JY54注射液”在受试者中的安全性、耐受性、药代动力学和药效动力学。据介绍，“JY54注射液”是公司自主研发的一款长效胰淀素类似物。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20241126155519150_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20241126155519150_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502069/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502069/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02566","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}